# Gregory Winter

> Gregory Winter is a Series A investor at Bicycle Therapeutics backing Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bicycle Therapeutics](https://shizune.co/investors/profile/bicycle-therapeutics)
- Location: Cambridge, United States
- Total investments: 2
- Last investment: Sep 2024
- Lead investor: 50%
- Last updated: Aug 2026

Gregory Winter is a Series A investor at Bicycle Therapeutics in Cambridge focused on Biotechnology and Electric Vehicle. Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge and most of his scientific career was based there. He was Head of Division of Protein and Nucleic Acid Chemistry, succeeding Cesar Milstein and has served as both Deputy and Acting Director of the LMB. He is a Fellow of theRoyal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge.Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing respectively and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies. He invented techniques to humanise rodent antibodies for use as therapeutics (1986–), working with H. Waldmann in the development of alemtuzumab/Campath-1H. Later, in competition with R. Lerner, he developed methods to make fully human antibodies (1989–) against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the US FDA. Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT,1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics. CAT was floated on the London Stock Exchange in 1997 and was responsible for the co-development of the therapeutic antibodies adalimumab/Humira and belimumab/Benlysta. CAT was acquired by AstraZeneca in 2006. Domantis developed a range of product leads based on single antibody domains and was acquired by GSK in 2006 in a private sale.Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (US) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008.In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 50% |
| Electric Vehicle | 1 | 50% |
| Machine Learning | 1 | 50% |
| Autonomous Vehicles | 1 | 50% |
| Artificial Intelligence | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Constructive Bio | Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | $57.7M | Series A | Sep 24, 2024 |  |
| Wayve | Wayve develops autonomous driving technology using end-to-end deep learning models that enable vehicles to navigate complex urban environments. The company builds AI software that learns directly from data collected through cameras and sensors, reducing reliance on high-definition maps and rule-based systems. Its approach focuses on embodiedintelligence, where the system improves driving performance through large-scale real-world training and simulation. Wayve partners with automotive manufacturers and fleet operators to integrate its driving software into production vehicles. The platform is designed to adapt to different geographies and driving conditions through continuous learning and model refinement. | $19.8M | Series A | Aug 01, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Eclipse](https://shizune.co/investors/profile/eclipse-ventures) — VC Fund, 2 deals together
- [Balderton Capital](https://shizune.co/investors/profile/balderton-capital) — VC Fund, 1 deal together
- [Exor Ventures](https://shizune.co/investors/profile/exor-seeds) — VC Fund, 1 deal together
- [EXOR N.V.](https://shizune.co/investors/profile/exor-s-p-a) — VC Fund, 1 deal together
- [Exor Ventures](https://shizune.co/investors/profile/exor-ventures) — VC Fund, 1 deal together
- [Fine Structure Venture](https://shizune.co/investors/profile/fine-structure-venture) — VC Fund, 1 deal together

## About Bicycle Therapeutics

VC Fund · Cambridge, United Kingdom

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

5 contacts available at Bicycle Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Gregory Winter | Scientific Founders | https://shizune.co/investors/profile/gregory-winter-3 |
| Christian Heinis | Scientific Founders | https://shizune.co/investors/profile/christian-heinis |
| Judy Chuk | Head of US Operations | https://shizune.co/investors/profile/judy-chuk |
| Kevin Lee | Chief Executive Officer | https://shizune.co/investors/profile/kevin-lee-b9ba |
| Lee Kalowski | Chief Financial Officer | https://shizune.co/investors/profile/lee-kalowski |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gregory Winter invest in?

Gregory Winter invests primarily in Biotechnology, Electric Vehicle and Machine Learning startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gregory Winter last invest?

The most recent investment recorded for Gregory Winter closed in Sep 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co